The results, which the companies said were statistically significant but haven’t been reviewed by independent scientists, suggest promise for an emerging but unproven class of vaccines that aim to treat diseases rather than prevent infections like typical shots.
If the combination proves successful in further testing, the results could broaden the applications for Moderna’s messenger RNA platform beyond the Covid-19 vaccine that was the first use for the gene-based technology.
oncy is already in relationships with merck and pfizer and pfizer, together with biontech, developed an mrna covid vaccine.
all of this maybe a bit more "down the line" than we would like, but then again all playing into an overall approach to deal with cancer.
back in 2015 had some correspondence with brad thompson excerpted here:
To: notan@oncolytics.ca
Sent: 2/13/2015 6:55:19 A.M. Eastern Standard Time
Subj: dna based testing
dr. thompson:
dave (u.s. based shareholder of oncy) here again.
are you familiar with the company exact science? they have developed and had approved a dna based test to detect colorectal cancer.
with the potential of reolysin to seek out cancer cells, any thoughts on reo, when introduced iv, that it might seek and destroy cancer cells in a matter of days/weeks and show up in either human waste or via a blood draw such that a dna test could detect cancer very early before it showed up in a more conventional manner and then if a cancer positive result were to occur to then place a patient on a reo regimen way before it might otherwise be prescribed?
thanks, dave
great news on the orphan approvals and the possibility of more to come. congratulations to you and the team at oncy.
___________
Sent: Monday, February 16, 2015 9:01 AM
To: Brad Thompson
Subject: Fwd: dna based testing
know you are busy, but just sending again just in case it got lost in transition. thanks, dave
_____________
Dave:
You are right, I didn't get the first one. Thanks for resending.
I do know about Exact Science. Very neat stuff. It would be a great idea to do that study as you outlined. As soon as people accept ES's approach officially, I expect we will do just that!
Thanks re: Orphan approvals. A lot of work by our team and it paid off!
Brad
___________
i have felt for a long time that reo/pela had a real vaccine effect. as oncy's current data matures, it seems that is being proved out.
the real problem is that reo/pela has been administered way late in the game. if it takes weeks/months for the enhanced effect of reo/pela to be realized, doing it when a patient's immune system and ability to effectively fight off cancer has been so compromised as to be marginally effective seems to be missing the boat.
reo/pela should be more of a first line of defense (imo).
maybe these durability findings might support such an approach.